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THERAPEUTIC use of amiodarone (AMD), a Class III
antiarrhythmic drug is complicated by the development
of lung fibrosis (LF) and phospholipidosis (PL). In the
present study, the effectiveness of a PAF antagonist, WEB
2086, against AMD induced LF and PL has been tested in
hamsters. The animals were randomly divided into four
groups: (1) saline + H20; (2) WEB + H20; (3) saline
+ AMD; and (4) WEB + AMD. Saline or WEB (10 mg/kg
i.p.) was given 2 days prior to intratracheal instillation of
water or AMD (1.5/mo110.25 ml/100 g BW) and thereafter
daily throughout the study. Twenty-eight days after
intratracheal instillation, the animals were killed and the
lungs processed for various assays. The amount of lung
hydroxyproline, an index of LF, in saline + H20, WEB
+ H20, saline + AMD, and WEB + AMD groups were
959 + 46, 1035 + 51, 1605 + 85 and 1374 + 69 #g/lung,
respectively. Total lung PL, an index of phospholipidosis,
in the corresponding groups were 8.4 + 0.4, 8.3 + 0.3,
11.7 + 0.3 and 9.9/tg/lung. Lung malondialdehyde, an
index of lipid peroxidation and superoxide dismutase
activity in saline + H20 WEB + H20, saline + AMD,
and WEB + AMD were 93.0 + 4.3, 93.0 + 2.7, 138.9 + 6.0
and 109.0 + 3.8 nmol/lung and 359.7 + 13.9, 394.0 + 22.8,
497.5 + 19.7 and 425.5 + 4.9 units]lung, respectively. Ad-
ministration of AMD alone caused significant increases in
all the above indexes of lung toxicity, and treatment with
WEB 2086 minimized the AMD induced toxicity as
reflected by significant decreases in these indexes.
Histopathological studies revealed a marked reduction in
the extent and severity of lung lesions in the WEB + AMD
group compared with the saline + AMD group. Treatment
with WEB 2086 also reduced the acute mortality from 35%
in saline + AMD group to 22% in WEB + AMD group.
It was concluded that PAF is involved in the AMD
induced lung fibrosis and phospholipidosis and that the
PAF receptor antagonist may, therefore, be potentially
useful in reducing AMD induced lung toxicity.
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Introduction
Amiodarone (AMD) was originally introduced as
an anti-anginal drug, but subsequently it was
shown to possess an effective anti-arrhythmic
property.2 Currently, AMD is considered to be a
Class III anti-arrhythmic drug and its use has been
increasing in recent years for the treatment of
resistant ventricular and supraventricular arrhyth-
mia.3’4 However, the clinical uses of this anti-
arrhythmic drug are severely limited due to
manifestations of serious pulmonary complications
which range from subacute necrotizing pneumoni-
tis to pulmonary fibrosis5-8 as well as phospholipid-
osis.9 Intratracheal (i.t.) instillation of AMD in
hamsters as a single bolus induces pulmonary
fibrosis which is initially characterized by interstitial
pneumonitis that progresses to fibrosis. 1’1 Since
(C) 1993 Rapid Communications of Oxford Ltd
the features of interstitial pulmonary fibrosis
induced by i.t. instillation of AMD in hamsters
resemble the idiopathic pulmonary fibrosis seen in
humans, this model has been used for elucidating
the underlying mechanisms of lung fibrosis and
phospholipidosis and for evaluating the effective-
ness of compounds as antifibrotic and antilipidotic
agents. 12 Using the AMD hamster model of lung
fibrosis and phospholipidosis, the effectiveness of a
platelet activating factor (PAF) receptor antagonist,
WEB 2086, as an antifibrotic and antilipidotic agent
has been evaluated.
Materials and Methods
Animals and reagents" Male Golden Syrian hamsters
weighing 112-128 g were purchased from Sasco,
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Inc. (Omaha, NE). The animals were housed four
per plastic cage and had access to tap water and
laboratory chow ad libitum. Bleomycin sulphate
(BlenoxaneR) was generously donated by Bristol
Laboratories (Division of Bristol Myers Co.,
Syracuse, NY). L-[3H](G)-hydroxyproline (specific
activity 5Ci/mmol) was obtained from ICN
Radiochemicals (Irvine, CA) and hydroxyproline
from Cal Biochem (San Diego, CA). Platelet
activating factor (PAF) antagonist, WEB 2086, was
a generous gift from the Boehringer Ingelheim
Pharmaceutics, Inc. (Ridgefield, CT). All other
reagents were of analytical grade and obtained from
standard commercial sources.
Treatment ofanimals: Hamsters were housed in groups
of four in plastic cages in facilities approved by the
American Association for the Accreditation of
Laboratory Animal care. They were acclimatized in
a special room with constant temperature and
filtered air for 1 week prior to the start of the
experiment. A 12h/12h light/dark cycle was
maintained and hamsters had access to water and
Rodent Laboratory Chow 5001 (Purina Mills, Inc.,
St Louis, MO) ad libitum. The hamsters were
randomly assorted into four experimental groups:
(1) saline + water; (2) WEB + water; (3) saline
+ AMD; (4) WEB + AMD. WEB 2086 was
dissolved in sterile isotonic saline and amiodarone
hydrochloride in sterile distilled deionized water at
60C. The AMD solution was stored at 4C,
protected from light. WEB 2086 (10 mg/kg) or an
equivalent volume of saline was administered
intraperitoneally once a day for 2 days prior to
intratracheal instillation of AMD (1.5/imol/0.25
ml/100 g BW) or an equivalent volume of water and
thereafter daily throughout the study. The
procedure of i.t. instillation was the same as
described previously. 13 Briefly, hamsters were first
anaesthetized with sodium pentobarbital (76-85
mg/kg i.p.) then AMD solution or an equivalent
volume of H20 was instilled intratracheally by
transoral route. All hamsters were sacrificed using
an overdose of sodium pentobarbital (120--125
mg/kg) at 28 days following the i.t. instillation and
their lungs were processed for morphological and
biochemical studies.
Processing of lungs for morphological studies: After
thoracotomy, the heart was ligated at its base to
isolate the vasculature. The lungs were fixed by
airway instillation with a cacodylate buffered
glutaraldehyde-paraformaldehyde fixative (400
mOSm, pH 7.0) at 30 cm of H20 pressure. Lungs
were fixed for at least 2 h, and blocks of tissue were
cut from at least two sagittal slabs from the left,
right cranial and right caudal lobes of each lung.
Each slab was dehydrated in 95% ethanol and
embedded in paraffin. Two sections from each lobe
were cut and stained with haematoxylin and eosin.
A lesion was defined as alveolitis consisting of
thickened intra-alveolar septa resulting from
oedematous swelling, fibrosis or the presence of
inflammatory cells in either interstitium or airways.
Processing of lungs for biochemical assay: Lungs of each
animal assigned to biochemical studies, were
perfused in situ through the right side of the heart
with 20 ml ice-cold isotonic saline. All lung lobes
were quickly excised free of nonparenchymal tissue,
washed in ice-cold saline, and then quickly frozen
in liquid nitrogen before storing at -80C.
Subsequently, the frozen lungs were thawed and
homogenized in 0.1 M KC1, 0.02 M Tris HC1 buffer
(pH 7.6) with a Polytron homogenizer (Brinkmann
Instruments, Inc., Westbury, NY). After thor-
oughly mixing the homogenate, its total volume
(10-11 ml) was recorded. Samples were divided into
aliquots and stored at -70C except the samples
for lipid peroxidation and collagen assays, which
were processed and assayed the same day the lungs
were homogenized. The activity of superoxide
dismutase (SOD) was determined on supernatant
resulting from the centrifugation of the lung
homogenate at 12 000 x g for 20 min at 4C.
Determination of hydroxyproline and proyl hydroxylase
activity: For assay of lung hydroxyproline as a
measure of collagen content, 1 ml of whole
homogenate was precipitated with 0.25 ml of
ice-cold 50% (w/v) trichloroacetic acid, centrifuged
and the precipitate hydrolyzed in 2 ml of 6 N HC1
for 18h at 110C. [3H]-hydroxyproline (1 x 105
dpm) was added to each sample as an internal
standard to determine recovery and the hydro-
xyproline content was measured by the method of
Woessner. 14 The hydroxyproline content for each
sample was then corrected for its recovery which
ranged from 75 to 85%. The method for propyl
hydroxylase assay was the same as reported in a
previous paperis and is based on the release of
tritium from 3,4-[3H]-proline labelled unhydrox-
ylated procollagen as substrate prepared in vitro with
10-day-old embryonic chick tibiae. During the
reaction, tritium is released in stoichiometric
proportion to propyl hydroxylation as 3H20 which
is counted and used as a measure of the prolyl
hydroxylase activity. The activity was expressed as
the total number of dpm released/lung/30 min.
Determination of lipid peroxidation and SOD activity: The
lung malondialdehyde equivalent (MDAE) as an
index of lipid peroxidation, was determined in the
whole homogenate according to the method of
Ohkakwa et al. 16 The SOD activity in the
supernatant was measured from the rate at which
the autoxidation of adrenaline to its adrenochrome
was inhibited. 17 The rate of adrenochrome forma-
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tion was 0.025 absorbance unit/min at 480 nm in a
Varian carry 219 spectrophotometer (Beckman
Instruments, Palo Alto, CA). Under these defined
conditions, the amount of tissue required to inhibit
the rate of adrenochrome formation by 50% (i.e.
0.0125 absorbance unit/min) was defined to contain
1 unit of SOD activity.
Determination of lung phospholipid: The total phospho-
lipid from the whole lung homogenate was
extracted in a mixture of chloroform and methanol
using the method of Bligh and Dyer18 with slight
modification to maximize the phospholipid re-
covery. Briefly, 0.5 ml of the homogenate was
mixed with 2 ml of chloroform, 2 ml methanol and
1.3 ml of double distilled water and homogenized
with a Polytron. After separating the two phases by
centrifugation, the upper alcoholic phase was gently
aspirated and discarded followed by addition of
another 1 ml of chloroform. Samples were vortexed
and the two phases were separated by centrifuga-
tion. After removing the upper phase, the
chloroform layer containing the phospholipid was
evaporated to dryness under nitrogen. Total lipid
phosphorous was quantitated by the method of
Ames and Dubin. 19 Phospholipid values are
reported as micromoles per total lung.
Statistical analysis of data" All data are expressed on
the basis of total lung. Expression of the data on a
per lung basis avoids the artifactual lowering of the
values in AMD treated animals due to the presence
of proteins of extrapulmonary origin.2 Values are
reported as the mean -k S.E.M. and the data were
analysed by a one-way analysis of variance and
Fisher’s least significant difference multiple compar-
ison text (Number Cruncher Statistical Analysis
System Version 5.1). A value of p < 0.05 was
considered significant.
Results
Body weight: The effect of daily administration of
WEB 2086 on body weight of hamsters with and
without i.t. instillation of amiodarone is shown in
Fig. 1. Although all amiodarone treated animals
initially lost weight thereafter, they gradually
gained weight and caught up with the hamsters in
either saline or WEB control groups at 2 weeks
after the i.t. instillation. In fact there were no
significant differences in body weight among the
four groups of hamsters at the time the experiment
was terminated.
Mortality: Intratracheal instillation of AMD caused
a 35% mortality (seven out of 20 died) in the saline
-F AMD group within 48 h post-treatment as
opposed to 22% mortality (four out of 18 died) in
the WEB + AMD group over the same period of
Saline WEB Saline WEB
+Water +Water +AMD +AMD
150
140
130
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100
0
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Days after i.t. instillation
FIG. 1. Effects of intratracheal instillation of water or amiodarone (AM D)
with or without treatment of WEB 2086 on body weight of hamsters.
WEB 2086 (10 mg/kg) or an equivalent volume of saline was injected
intraperitoneally once a day for 2 days prior to intratracheal instillation of
AMD (1.5/mol/0.25 ml/100 g BW) or an equivalent volume of sterile
distilled water and thereafter daily throughout the study. Hamsters were
weighed twice a week and on the 28th day, the experiment was
terminated. Each point represents the mean -I-S.E.M. of 12-14 animals
in each group.
time. There was no mortality in saline -F water
(0/12) and WEB -F water (0/12) groups at any time
of the study.
Lung hydroxyproline content and prowl hydroxylase activity:
The eEects of daily treatment with WEB 2086 on
AMD induced increases in lung hydroxyproline and
prolyl hydroxylase activity are shown in Figs 3 and
4, respectively. Intratracheal instillation of AMD
significantly increased the lung hydroxyproline
content to 167% of saline control. Treatment with
WEB 2086 caused a significant attenuation in the
AMD induced increase in lung hydroxyproline
content in the WEB -F AMD group, although the
hydroxyproline level in the latter group was still
significantly higher than that of saline -F H20 or
WEB + H20 group (Fig. 2). Similarly, i.t.
instillation of AMD alone increased the lung prolyl
hydroxylase activity significantly to 218% of the
20O0
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Water Water AMD AMD
FIG. 2. Effects of WEB 2086 on amiodarone (AMD) induced increases in
hydroxyproline content of hamster lungs. See the legend to Fig. for
treatment details. Each value represents the mean ___S.E.M. of eight
animals in each group. Significantly higher (p < 0.05) than all other
groups, Significantly higher (p < 0.05) than saline + water and WEB
-t- water groups.
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FIG. 3. Effects of WEB 2086 on amiodarone (AMD) induced increases in
prolyl hydroxylase activity of hamster lungs. See the legend to Fig. for
treatment details. Each value represents the mean _+S.E.M. of eight
hamsters in each group. Significantly higher (p_< 0.05) than saline
+ water and WEB + water groups.
saline + H20 group. However, daily treatment
with WEB 2086 had no effect on AMD induced
increase in the lung prolyl hydroxylase activity in
the WEB + AMD group. In fact the activity in the
latter group of animals was significantly increased
to 235% of the saline control. There was no
significant difference in the lung prolyl hydroxylase
activity between the saline -F AMD and WEB
+ AMD groups (Fig. 3).
Lung MDAE and SOD activity: lntratracheal instilla-
tion of AMD significantly increased the lung
MDAE content to 149% of saline -F H20 control
at 28 days post-treatment (Fig. 4). Administration
of WEB 2086 once a day over the same period
caused a significant reduction in the AMD induced
increase in the lung MDAE content in the WEB
-F AMD group, although the MDAE level in this
group was still significantly higher than that of
saline -F H20 or WEB -F H20 control group. The
60 f500400
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FIG. 5. Effects of WEB 2086 on amiodarone (AMD) induced increases in
superoxide dismutase activity of hamster lung. See the legend to Fig.
for treatment details. Each value represents the mean -I-S.E.M. of eight
hamsters in each group. Significantly higher (p _< 0.05) than all other
groups, Significantly higher (p _< 0.05) than saline + water group but
not WEB + water group.
lung SOD activity in the AMD treated group was
also significantly increased to 138% of saline + H20
control and treatment with WEB 2086 attenuated
significantly the AMD induced increase in the lung
SOD activity in the WEB -F AMD group, although
the activity in this group remained significantly
higher than that of saline -F H20 but it did not
differ significantly from that of the WEB + H20
group (Fig. 5).
Lung total phospholipid content: The effect of i.t.
instillation of AMD in hamsters with and without
WEB 2086 treatment is summarized in Fig. 6. There
was a significant increase in the total phospholipid
content of the lungs to 138% of the saline + H20
control and treatment with WEB 2086 reduced the
AMD induced increase in the lung phospholipid
level significantly in the WEB -F AMD group,
although the level in this group was still
significantly higher than that of saline -F H20 or
WEB -F H20 groups.
200
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FIG. 4. Effects of WEB 2086 on amiodarone (AMD) induced increases in
malondialdehyde equivalent level in hamster lung. See the legend to Fig.
for treatment details. Each value represents the mean
___
S.E.M. of eight
hamsters in each group. Significantly higher (p < 0.05) than all other
groups, t Significantly higher (p _< 0.05) than saline + water and WEB
-t- water groups.
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FIG. 6. Effects of WEB 2086 on amiodarone (AMD) induced increases in
total phospholipid content of hamster lung. See the legend to Fig. for
treatment details. Each value represents the mean -I-S.E.M. of eight
hamsters in each group. Significantly higher (p < 0.05) than all other
groups, Significantly higher (p < 0.05) than saline + water and WEB
+ AMD groups.
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Histopathology: The histopathological study was
performed in four to six hamsters per group.
Histopathological evaluation of saline + H20 and
WEB + H20 groups revealed normal pulmonary
parenchymal tissue which was characterized by a
lack of any notable aggregation of inflammatory
cells in alveolar spaces or the interstitium, and thin
interalveolar septa (Fig. 7A,B). In contrast, lungs
from hamsters in the saline + AMD group had
lesions that ranged from multifocal proximal acinar
interalveolar septal thickening and aggregations of
airway inflammatory cells to multifocal fibrotic
lesions that obliterated airspaces and showed
abundant fibroblasts and collagen (Fig. 7C). On
average, about 10% of each lobe had pulmonary
lesions in this group. The pulmonary lesions in the
hamsters of WEB + AMD group were limited to
multifocal proximal acinar, interalveolar septal
thickening and aggregation of airway inflammatory
cells and some peripheral interalveolar septal
thickening with more mononuclear inflammatory
cells and less fibroblasts and collagen in the
interstitium (Fig. 7D). There was a marked
reduction in the extent and severity of the lesion in
the WEB + AMD group compared with the saline
/ AMD group.
Discussion
Consistent with the authors’ previous study as
well as with the studies of other investigators, i.t.
instillation of AMD caused significant increases in
lung collagen and phospholipid content. 1-12 In the
present study, earlier findings that AMD treated
hamsters had twice as much prolyl hydroxylase
activity per lung as the hamsters in control groups
were also confirmed. 12 There are several proposed
underlying mechanisms for the pathogenesis of
AMD induced lung injury,2>23 including oxidation
via generation of reactive oxygen species (ROS)’24
The potential biochemical mechanisms responsible
for the oxidant effect of AMD is not known. Li and
Chignel125 found that UV irradiation of AMD and
its desethyl metabolite produced a carbon-centred
radical capable of abstracting a hydrogen atom from
linoleic acid and forming the corresponding
pentadienyl radical. Reaction of the pentadienyl
radical with oxygen in vivo would yield a peroxyl
radical responsible for propagation of a chain of
lipid peroxidation.
It is conceivable that PAF may be one of the
products resulting from the peroxyl radical induced
oxidation of the phospholipid membrane of cells.
FIG. 7 Effects of WEB 2086 on amiodarone IAMD) induced parenchymal lesions of hamster lungs. See the legend to Fig. for treatment details. (A)
A representative micrograph of lungs from hamsters in the saline + water group shows normal terminal broncheoles, alveolar ducts and thin interalveolar
septa. (B) A representative micrograph of lungs from hamsters in the WEB + water group shows normal terminal bronchioles, alveolar ducts and thin
interalveolar septa. (C) A representative micrograph of lungs from hamsters in the saline + AM D group shows abnormal small airways with aggregations
of airway inflammatory cells (arrowheads). Note the adjacent areas of thickened septa and organized connective tissue. (D) A. representative micrograph
of lungs from hamsters in the WEB + AM D group shows an abnormal small airway and a few thickened septa. Note the reduced severity of inflammation
and fibrosis in this treatment group. A arteriole, TB terminal bronchiole, AD alveolar duct, ASA abnormal small airways, CT organized
connective tissue, bar 100 #m.
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This hypothesis is based on evidence available in
literature that ROS such as H202 stimulates the
synthesis of PAF in primary cultures of bovine
pulmonary artery endothelium and human umbili-
cal vein endothelium.26 Compared with other lipid
mediators of inflammation, such as those generated
via the cyclooxygenase or lipoxygenase pathway,
PAF has a wider range of inflammatory effects on
many cell types including activation of neutrophils,
eosinophils, lymphocytes and macrophages. The
stimulation of neutrophils by PAF results in the
release of lysosomal enzymes and superoxide
anions and the generation of LTB4 .27-29 PAF also
increases the production of superoxide anion by
human alveolar macrophages in a dose dependent
3Omanner.
Our data support the notion that PAF is involved
in the AMD induced lung toxicity via generation
of superoxide radicals. Involvement of this radical
is indirectly suggested by the increase in lung
superoxide dismutase (SOD) activity that was
found after AMD treatment. Increase in the SOD
activity is presumably a compensatory defence
mechanism to protect tissue against the deleterious
effects of superoxide radicals. 31 However, the
increase in the activity of this enzyme as a
consequence of enhanced cellularity in the lung due
to inflammatory and reparative processes cannot be
ruled out. Increase in the lung MDAE content
which is conventionally used as an index of lipid
peroxidation, that was found after AMD also
suggests the role of superoxide radical in AMD
induced lung toxicity. Furthermore, it has been
demonstrated that superoxide anions stimulate
collagen synthesis by modulating differential
collagen gene expression of fibroblasts in culture.32
This finding may help explain the AMD induced
increase in the lung collagen content as found in
the present study.
The biochemical findings that WEB offers
protection against AMD induced lung toxicity are
in corroboration with the histological findings since
hamsters in the WEB + AMD group showed a
marked reduction in the extent and severity of lung
inflammation and fibrosis as compared with
hamsters in saline + AMD group. It appears that
generation of superoxide anions resulting from
activation of lung neutrophils and macrophages by
PAF could be one of the possible factors in the
pathogenesis of AMD induced lung fibrosis and
phospholipidosis. This was substantiated by the
biochemical and histological findings of the present
study that PAF receptor antagonist (WEB 2086)
attenuated most of the indices of lung toxicity
caused by i.t. instillation of AMD.
It is surprising that WEB 2086 caused significant
reductions in AMD induced increases in the lung
collagen and phospholipid content but it had no
effect on increased lung prolyl hydroxylase activity.
The prolyl hydroxylase catalyses hydroxylation of
proline residues on nascent procollagen polypep-
tides before helix formation and secretion.33
Although this is not a rate-limiting step in collagen
synthesis,34 increased activity of this enzyme
frequently predates collagen accumulation in
experimental models of fibrosis, ls’3s However, it
should be noted that tranilast, which is used for
treatment of bronchial asthma and allergic rhinitis,
was found to specifically suppress the collagen
synthesis of fibroblast from keloid and hypertrophic
scar tissue but had no effect on prolyl hydroxylase
activity except at an extremely high concentration.36
There are several lines of evidence which suggest
that increased production of PAF may be
responsible for a variety of inflammatory condi-
tions. For instance, increased production of PAF as
reflected by its elevated blood level was implicated
in the impaired haemodynamics of cirrhotic
patients.3v Recently, Zhou et al.38 demonstrated that
increased production of PAF from Kupffer cells
may be an important mediator for the hepatic
inflammation resulting from a short-term ligation
of bile duct. An increased production of PAF has
been implicated in the pathophysiology of a variety
of pulmonary disorders including airway micro-
vascular leakage, mucous production, bronchial
asthma, adult respiratory distress syndrome and
pulmonary hypertension.39 It has been suggested
that PAF is also involved in the bronchopulmonary
dysplasia resulting from chronic lung injury which
eventuates in airway obstruction, pulmonary
oedema, pulmonary hypertension and interstitial
fibrosis.4
Interaction of PAF with its specific receptor
promotes multiple biochemical pathways, each of
which contributes to the process of cellular
activation.4 These pathways include activation of
a GTPase that inhibits adenylate cyclases; stimula-
tion of Ca2 + stores and activation of phospholipases
that yield diacyglycerol, inositol triphosphate and
free arachidonic acid which can be acted upon
through the cyclooxygenase and lipoxygenase
pathways to give eicosanoids.42 It is interesting and
consistent with the above PAF receptor interaction
hypothesis that the authors previously reported an
inhibition of adenylate cyclase,43 increased in-
tracellular level of calcium,44 increased lung
phospholipase A2 activity4s and increased plasma46
and lung4 levels of some eicosanoid in a bleomycin
hamster model of pulmonary fibrosis.
The findings reported in this study that the PAF
receptor antagonist (WEB 2086) not only offered
protection against the acute toxicity but it also
ameliorated lung fibrosis and phospholipidosis at 28
days after i.t. instillation of AMD, suggest that
PAF is involved in the pathogenesis of fibrotic and
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phospholipidotic processes. The results are con-
sistent with the results of Rodriguez-Barbero et a1.48
who found that treatment with the PAF receptor
antagonist, BN 52021, markedly attenuated the
gentamicin induced nephrotoxicity in rats. How-
ever, the present findings should be interpreted
cautiously with respect to the effectiveness of WEB
2086 in attenuating the AMD induced lung fibrosis
and phospholipidosis in humans in therapeutic
situations for two reasons. First, i.t. instillation of
AMD in hamsters does not simulate oral
administration of this drug in humans and second,
the fibrosis that results in hamsters may not be
comparable to what occurs in humans in clinical
situations. Nevertheless, use of WEB 2086 in the
AMD hamster model of lung injury has opened a
potentially novel approach in the management of
lung fibrosis and phospholipidosis.
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